Protocol for "Development and characterization of a non-human primate model of diseeminated synucleinopathy"

DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

Here we took advantage of a retrogradely-spreading adeno-associated viral vector

serotype 9 coding for the alpha-synuclein A53T mutated gene to induce a

widespread synucleinopathy of cortical and subcortical territories innervating

the putamen. Four weeks post-AAV deliveries animals were sacrificed and a

comprehensive biodistribution study was conducted, comprising the

quantification of neurons expressing alpha-synuclein, rostrocaudal distribution

and their specific location.

This collection is made of (1) study design, (2) experimental animals, (3) viral vector production, (4) stereotaxic surgery for AAV deliveries, (5) necropsy, tissue processing and data analysis, (6) quantification of neurons expressing alpha-synuclein, (7) quantification of the nigrostriatal system

4 literature references included

3 figures included, as follows:

• Figure 1: Viral vector (synapsin)AAV9-SynA53T

• Figure 2: Ventriculography-assisted stereotaxic surgery

• Figure 3: Quantification of alpha-synuclein positive neurons

Figure 1 (plasmid map & sequence).pdf Figure 2 (Rx ventriculographies).tif Figure 3 (method cell count).tif PROTOCOL Rico et al (2023).docx PROTOCOL Rico et al (2023).pdf